Balanced news tone
News Sentiment
INKT sentiment intelligence
Mink Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
60 relevant articles
News tone and price action are not far from neutral.
81/100 classification confidence.
directly relevant articles
high-authority source matches
-3.5% over one week, -12.2% over four weeks, trend inactive, and near fair-value range.
Here's Why You Should Add INKT Stock to Your Portfolio Now
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
81/100 classification
One-week reaction
-3.5%
Price reacting lower
Trend fit
Trend inactive
-12.2% over four weeks
Fair value
-1.2%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
46
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingKey
Direct company coverage
Mink Therapeutics Inc (INKT) Institutional Confidence
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 21:56
- Source
- TradingKey
Investing.com
Direct company coverage
Mink Therapeutics director Barbara Ryan sells $19,141 in stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- Investing.com
GlobeNewswire
Direct company coverage
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 20:30
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 13:04
- Source
- GlobeNewswire
marketscreener.com
Direct company coverage
Mink Therapeutics Doses First Patient in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- marketscreener.com
Investing.com
Direct company coverage
Why is Mink Therapeutics stock surging today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- Investing.com
GlobeNewswire
Direct company coverage
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 15:07
- Source
- GlobeNewswire
Market source
Direct company coverage
We're Not Very Worried About MiNK Therapeutics' (NASDAQ:INKT) Cash Burn Rate
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 18 May 2026 07:00
- Source
- Market source
GuruFocus.com
Direct company coverage
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Strategic Advances and Financial ...
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 23:01
- Source
- GuruFocus.com
MarketBeat
Direct company coverage
MiNK Therapeutics Q1 Earnings Call Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 14:12
- Source
- MarketBeat
GlobeNewswire
Direct company coverage
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 11:30
- Source
- GlobeNewswire
Investing.com
Direct company coverage
Earnings call transcript: MiNK Therapeutics Q1 2026 shows strategic progress
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- Investing.com
Quiver Quantitative
Direct company coverage
MINK THERAPEUTICS ($INKT) Releases Q1 2026 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- Quiver Quantitative
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
GlobeNewswire
Direct company coverage
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 11:30
- Source
- GlobeNewswire
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
MiNK Therapeutics, Inc. Q4 2025 Earnings Call Summary
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 31 Mar 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Investing.com Nigeria
Direct company coverage
MiNK Therapeutics stock soars 80% on C-Further collaboration By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Mar 2026 11:15
- Source
- Investing.com Nigeria
StocksToTrade
Direct company coverage
MiNK Therapeutics Stock Gains Amid New Market Developments
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- StocksToTrade
Tokenist
Direct company coverage
Why Did MiNK Therapeutics (INKT) Stock Jump 50% Premarket Today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- Tokenist
Quiver Quantitative
Direct company coverage
MiNK Therapeutics jumps on pediatric cancer collaboration and non-dilutive funding news
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- Quiver Quantitative
Investing News Network
Direct company coverage
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Nov 2025 08:00
- Source
- Investing News Network
Zacks Investment Research
Direct company coverage
Should I buy MiNK Therapeutics, Inc. (INKT)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Aug 2025 07:00
- Source
- Zacks Investment Research
simplywall.st
Direct company coverage
MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 787% last week
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2025 07:00
- Source
- simplywall.st
Stocktwits
Direct company coverage
MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 11 Jul 2025 07:00
- Source
- Stocktwits